Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Nivolumab 4Magnetic Resonance Spectroscopy 4fludarabine 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3ulixertinib 2sargramostim 2X-Rays 2Trastuzumab 2Sunitinib 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Oxaliplatin 2Melphalan 2Leucovorin 2FAPI-46 2Erlotinib Hydrochloride 2Cryosurgery 2Crizotinib 2Capecitabine 2Busulfan 2Bevacizumab 2trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sapanisertib 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × olutasidenib × CNS × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡